Literature DB >> 6145468

Effects of dopamine and bromocriptine on colonic motility in dog.

L Bueno, M J Fargeas, J Fioramonti, C Honde.   

Abstract

The effects of intravenous infusions of dopamine (0.1 to 1 mg kg-1h-1) and bromocriptine (10 to 40 micrograms kg-1h-1) on colonic motility were investigated in fasted dogs fitted with permanent strain gauges on the ascending, transverse and descending colon. Infused at rates of 0.5 and 1 mg kg-1h-1 during 1 h, dopamine immediately stimulated the motility of the descending colon; after a delay of 40 to 60 min this effect was balanced by an inhibition of the motility of the ascending and transverse colon. Bromocriptine infused intravenously at doses of 10 to 40 micrograms kg-1h-1 stimulated the motility of the whole colon but these effects were limited to the duration of the infusion (60 min). Both propranolol (0.5 mg kg-1) and tolazoline (2 mg kg-1) failed to block the effects of dopamine and bromocriptine whereas phentolamine (0.1 mg kg-1) and prazosin (0.2 mg kg-1) partially reduced the inhibitory effects of dopamine on the proximal colon. Haloperidol at doses higher than 0.2 mg kg-1 and domperidone blocked the bromocriptine-induced stimulation of colonic motility which was unaffected by previous treatment with alpha- and beta-adrenoceptor blocking agents. These results suggest that in the dog, dopamine and bromocriptine stimulate colonic motility through specific dopamine receptors. However, they suggest that the inhibitory effects of dopamine on the proximal colon which are blocked by dopamine antagonists are also partially due to an effect on alpha 1-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145468      PMCID: PMC1987238          DOI: 10.1111/j.1476-5381.1984.tb16439.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  A dopamine receptor in esophageal smooth muscle of the opossum.

Authors:  D J de Carle; J Christensen
Journal:  Gastroenterology       Date:  1976-02       Impact factor: 22.682

2.  The "spastic colon" syndrome: therapeutic and pathophysiologic considerations.

Authors:  F Lechin; B Van Der Dijs; A Bentolila; F Peña
Journal:  J Clin Pharmacol       Date:  1977-07       Impact factor: 3.126

Review 3.  Cardiovascular and renal actions of dopamine: potential clinical applications.

Authors:  L I Goldberg
Journal:  Pharmacol Rev       Date:  1972-03       Impact factor: 25.468

4.  Affinities of drugs for the agonist and antagonist states of the dopamine receptor.

Authors:  D R Riddall; W J Leavens
Journal:  Eur J Pharmacol       Date:  1978-09-15       Impact factor: 4.432

5.  Stimulation of 3H-apomorphine binding by dopamine and bromocriptine.

Authors:  H A Robertson
Journal:  Eur J Pharmacol       Date:  1980-01-25       Impact factor: 4.432

6.  A miniature transducer for recording intestinal motility in unrestrained chronic rats.

Authors:  X B Pascaud; M J Genton; P Bass
Journal:  Am J Physiol       Date:  1978-11

7.  Dopamine as a possible neurotransmitter in gastric relaxation.

Authors:  J E Valenzuela
Journal:  Gastroenterology       Date:  1976-12       Impact factor: 22.682

8.  Antidiarrheal effects of dihydroergotamine.

Authors:  F Lechin; B Van Der Dijs; A Bentolila; F Peña
Journal:  J Clin Pharmacol       Date:  1977 May-Jun       Impact factor: 3.126

9.  Motor effect of dopamine on human sigmoid colon. Evidence for specific receptors.

Authors:  G A Lanfranchi; L Marzio; C Cortini; E M Osset
Journal:  Am J Dig Dis       Date:  1978-03

10.  Effects of dopaminergic blocking agents on distal colon motility.

Authors:  F Lechin; B Van Der Dijs
Journal:  J Clin Pharmacol       Date:  1979-10       Impact factor: 3.126

View more
  3 in total

1.  Dopamine induces inhibitory effects on the circular muscle contractility of mouse distal colon via D1- and D2-like receptors.

Authors:  Michelangelo Auteri; Maria Grazia Zizzo; Antonella Amato; Rosa Serio
Journal:  J Physiol Biochem       Date:  2017-06-09       Impact factor: 4.158

Review 2.  Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.

Authors:  Vinod Metta; Valentina Leta; Kandadai Rukmini Mrudula; L K Prashanth; Vinay Goyal; Rupam Borgohain; Guy Chung-Faye; K Ray Chaudhuri
Journal:  J Neurol       Date:  2021-04-21       Impact factor: 4.849

Review 3.  Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.

Authors:  Sebastiaan P van Kessel; Sahar El Aidy
Journal:  Front Neurol       Date:  2019-10-15       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.